RSV is a highly-contagious virus that causes inflammation in the lower airways.
While most people recover in a few weeks, RSV can be serious. Infants and older adults are most likely to develop severe RSV symptoms that may require hospitalization. The immunizations were developed to provide needed protection against the dangerous and sometimes life-threatening virus.
- Difficulty breathing
- Runny nose
- Decreased appetite
Adults age 60 and older may receive a single dose of an RSV vaccine seasonally, especially those with an underlying medical condition that makes them at greater risk for severe RSV infection.
Pregnant women can receive a seasonal administration of one dose of an RSV vaccine weeks 32 through 36 of pregnancy from September through January. This vaccine is designed to help protect newborns from severe RSV illness.
Infants and young children can receive nirsevimab, a monoclonal antibody product that is considered a passive immunization. Although nirsevimab is not an active immunization, it works in a manner similar to routine childhood vaccines. One dose of nirsevimab is expected to last at least five months, about the length of a typical RSV season.
- Nirsevimab is recommended for newborns and high-risk infants less than 19 months of age from October through March.*
*Marshfield Clinic Health System and the nation are experiencing shortages of nirsevimab. The maternal vaccination may be the preferred way to ensure that your infant will be protected against RSV.
Learn more about the Centers for Disease Control and Prevention (CDC) RSV vaccine recommendations.
Talk to your insurance carrier before receiving your RSV immunization
Coverage may change depending on your insurance carrier. Patients are encouraged to call to discuss coverage options prior to making an appointment to receive their vaccine.